On August 2, 2018 RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform, reported that the European Patent Office (EPO) and Japan Patent Office (JPO) have granted patents for the Company’s novel self-delivering RNAi (sd-rxRNA) therapeutic platform (Press release, RXi Pharmaceuticals, AUG 2, 2018, View Source [SID1234528839]). The EPO Patent #: 2949752 B1 and JPO Patent #: 620309 cover composition of matter, specifically structural and chemical attributes of sd-rxRNA. These patents will be set to expire in 2029.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased that both the European and Japan Patent offices have recognized our novel therapeutic platform with the granting of these patents," said Dr. James Cardia, Vice President of Business Operations at RXi Pharmaceuticals. He further added, "The Company recently reported the successful outcomes from both our dermatology and ophthalmology clinical trials where our lead candidate RXI-109, an sd-rxRNA therapeutic compound targeting connective tissue growth factor (CTGF), is being evaluated. We announced earlier this year that we would exclusively focus on developing the next generation of immuno-oncology therapeutics based on our self-delivering RNAi therapeutic platform. As such, we are actively seeking to partner or out-license both the Dermatology and Ophthalmology Franchises. The granting of these patents further provides for multiple commercial and development opportunities with RXI-109 and RXi’s sd-rxRNA technology platform, each broadly protected in the United States and International regions."